Lastly, with pre-clinical evidence that immune signaling through the cGAS/STING pathway promotes HRD, it is possible that STING agonists could synergize with PARPis in both BRCA- and PALB2-mutated as well as wild-type pancreatic tumors. This evidence concerns the gene STING1 and hypoparathyroidism-retardation-dysmorphism syndrome.